- Datum24.03.2026
- Uhrzeit17:00 - 18:00 Uhr
- Veranstalter
stock3
Santen Pharmaceutical Co. Ltd. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (L&S)
-0,58 %
Intraday
-8,02 %
1 Woche
-6,52 %
1 Monat
-0,58 %
Seit Jahresbeginn
0,00 %
1 Jahr
21,99 %
3 Jahre
-17,31 %
5 Jahre
Passender Service zu Santen Pharmaceutical Co. Ltd.
Webinar zu Santen Pharmaceutical Co. Ltd.
Kursinformationen (L&S)
- Tagestief / Hoch (€)-
- 52W-Tief / Hoch (€)7,850-10,200
- Jahrestief / Hoch (€)---
- Schlusskurs (Vortag)
- Eröffnungskurs
Wichtigste Eigenschaften
Dividenden von Santen Pharmaceutical Co. Ltd.
Termine von Santen Pharmaceutical Co. Ltd.
- Mai12Santen Pharmaceutical Co. Ltd.Q4 2025 Earnings Release
- Aug12Santen Pharmaceutical Co. Ltd.Q1 2026 Earnings Release
- Nov10Santen Pharmaceutical Co. Ltd.Q2 2026 Earnings Release
Beschreibung
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
